News

 

Below please find the latest news at M6P Therapeutics.

M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting

ST. LOUIS, Mo., – May 11, 2021 M6P Therapeutics, (“the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of preclinical proof-of-concept data for M002, its gene therapy candidate for mucolipidosis type II (MLII), at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting…

 

M6P Therapeutics Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ST. LOUIS, Mo., – April 28, 2021 M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today a poster presentation on mucolipidosis type II at the American Society of Gene & Cell Therapy’s (ASGCT) 24th Annual Meeting: May 11-14, 2021…

 

M6P Therapeutics Supports Rare Disease Day 2021 and Joins Global Movement to Increase Awareness of Rare Diseases

ST. LOUIS, Mo., – Feb. 11, 2021 M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its support for Rare Disease Day 2021 and commitment to the rare disease community. Rare Disease Day is an annual awareness day dedicated to elevating the public understanding of rare diseases and their impact on patients’ lives…

 

M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 17th Annual WORLDSymposium 2021

ST. LOUIS, Mo., – Feb. 11, 2021 M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today the presentation of promising preclinical data at the 17th Annual WORLDSymposium™, a research conference dedicated to lysosomal diseases being held virtually Feb. 8-12, 2021. In two separate poster presentations, M6P Therapeutics’ researchers report preclinical efficacy and safety results for Gaucher disease and mucolipidosis II (MLII) respectively…

 

M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board

ST. LOUIS, Mo., Feb. 3, 2021 M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its scientific advisory board (SAB) that will support the Company’s mission of translating its innovative bicistronic-S1S3 technology platform into best-in-class therapies that address unmet needs within the LSD community. The Company’s platform enables improved biodistribution of recombinant enzymes to target tissues and efficient cross-correction for gene therapies…

 

M6P Therapeutics Receives Six Rare Pediatric Disease Designations from the U.S. FDA for Company’s Deep Pipeline of Programs for Lysosomal Storage Disorders

ST. LOUIS, Mo., – Jan. 28, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that the U.S. Food and Drug Administration (FDA) granted six rare pediatric disease designations (RPDDs) for various programs within its development pipeline for LSDs, including four recombinant enzyme and two gene therapy programs. In addition, the FDA granted two orphan drug designations (ODDs) for its gene therapy programs for Gaucher disease and mucolipidosis…